KRAS and non-small cell lung carcinoma: ERK3 was also found to promote migration and invasiveness of both KRAS‐mutated and KRAS‐wild‐type NSCLC cells by phosphorylating steroid receptor coactivator 3 (SRC‐3), a bona fide oncogene [20].